Everest Clinical Research’s Post

Sniper Medical Technologiesの革新的なDQ24 Plus #dPCR Systemで医療技術の未来を切り拓いてください。このオールインワンシステムは診断の効率と精度を再定義します。革新的なVibroJectドロップレット生成技術を備えたDQ24 Plusは、医療検査の精度に新しい基準を設定します。 洗練された6チャンネル検出システムを搭載し、包括的かつ信頼性のある結果を確実にします。DQ24 Plusの特長は、世界で最もシンプルで直感的な操作モードを誇っています。複雑な手続きはもうありません。シームレスでわかりやすい機能だけです。 DQ24 PlusはすでにFDAおよびCE認証を取得しており、その信頼性と国際基準への遵守を確立しています。 医療診断の体験を洗練させ、シンプルで未来に対応した医療ソリューションを求めるなら、Sniper Medical TechnologiesのDQ24 Plusを選択してください。ここで革新が使いやすさと出会います。 Upgrade your medical diagnostic experience to a new level of sophistication and simplicity with Sniper Medical Technologies' groundbreaking DQ24 Plus #dPCR System. This all-in-one system redefines efficiency and precision in diagnostics. With the revolutionary VibroJect droplet generation technology, DQ24 Plus sets a new standard for accuracy in molecular diagnostics. Equipped with a sophisticated 6-channel detection system, it ensures comprehensive and reliable results. What sets DQ24 Plus apart is its unparalleled ease of use – boasting the world's simplest and most intuitive operation mode. No more complex procedures; just seamless and straightforward functionality. DQ24 Plus has already obtained FDA and CE certifications, solidifying its credibility and adherence to international standards. Choose DQ24 Plus from Sniper Medical Technologies for a future-ready molecular diagnostic solution, where innovation meets ease. https://lnkd.in/gvDJvqDx

💗 AngioDynamics launches RECOVER-AV study of AlphaVac F18⁸⁵ System for PE treatment According to the US-based medical technology company, the prospective, multicentre, multinational study will assess the efficacy, safety, and long-term functional outcomes of the system in treating the condition. The trial will evaluate the device’s ability to treat intermediate-risk PE through percutaneous mechanical aspiration thrombectomy, with the aim of facilitating its adoption in Europe. The RECOVER-AV study follows the completion of the APEX-AV (Acute Pulmonary Extraction Trial with AlphaVac), a previous single-arm trial conducted in the US under an Investigational Device Exemption. Read more online: https://lnkd.in/e9pneeBN 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Not all PFA system is the same.

Simply Bigger. The VASCADE MVP® XL Venous Vascular Closure System offers a 58% increase in collagen and 9% increase in disc size compared to VASCADE MVP®. Discover how VASCADE MVP® XL can make a difference for you and your patients today! https://hubs.ly/Q02LKTmP0 #SimplyBigger #ePeeps #Afib #VASCADEMVPXL

BIOTRONIK Receives FDA Breakthrough Device Designation (BDD) for Freesolve™ Below-the-Knee (BTK) Resorbable Magnesium Scaffold (RMS) designed for patients suffering from chronic limb-threatening ischemia (CLTI). To qualify for a Breakthrough Device Designation, a device technology must address an unmet need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating conditions. The goal of the program is to provide patients and clinicians with timely access to these breakthrough treatments by accelerating their development, assessment and review while maintaining regulatory standards for pre-market approval. Another new era for RMS begins! 👉 Read the press release here: https://ow.ly/SINs50QVlLJ #Freesolve #BIOTRONIK #PAD #CLIfighters #metallicnotplastic #leavelessbehind

https://lnkd.in/g4AQ4h2z Attending #SCOPESummit this month? Attend this session by Calyx's Lee Bardy and learn how advanced #IRT can help manage expected and emergency drug shortages, enabling you to plan, design, and adapt as your trial needs change. https://lnkd.in/gEMvKpVF #RTSM #ClinicalTrials #ChooseCalyx #Randomization #TrialSupplyManagement

The Tapered Enroute Transcarotid Stent System is here! The tapered configurations allow for more options in order to tailor to individual patient anatomy needs.

Announcing initiation of our phase 1 clinical study of BT-600 using the NaviCap™ targeted oral delivery platform: https://lnkd.in/gk3Vzbpx #clinicaltrial #IBD #ulcerativecolitis #NaviCap

After Resmetirom, hopefully we will have a few other approveed options for MASH Rx soon. Major Phase 2 MASH Trial Updates: Tirzepatide: 🔸44-62% resolution of MASH at 52 wks. 🔸~50% of participants ≥ 1 stage improvement in fibrosis at 52 wks. Survodutide: 🔸~35% of participants with ≥ 1 stage improvement in fibrosis at 48 wks.

The countdown begins! Are you attending World CB & CDx in London next week? Swing by our booth to discuss the latest companion diagnostics (CDx) innovations. Feel free to message us on LinkedIn to schedule a meeting or learn more. #cdx #companiondiagnostics #personalizedmedicine #worldcdx